Xenon Pharmaceuticals Inc. financial data

Symbol
XENE on Nasdaq
Industry
Pharmaceutical Preparations
Location
200 3650 Gilmore Way, Burnaby, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.37K % -31.5%
Debt-to-equity 4.56 % +22.3%
Return On Equity -24.4 % -21.7%
Return On Assets -23.3 % -20.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75.4M shares +18.7%
Common Stock, Shares, Outstanding 75.5M shares +19.6%
Entity Public Float 2.44B USD +29.9%
Common Stock, Value, Issued 1.44B USD +34.1%
Weighted Average Number of Shares Outstanding, Basic 77.6M shares +18.1%
Weighted Average Number of Shares Outstanding, Diluted 77.6M shares +18.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 172M USD +36.8%
General and Administrative Expense 51.8M USD +45.6%
Operating Income (Loss) -224M USD -39.3%
Nonoperating Income (Expense) 35.3M USD +148%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -189M USD -28.7%
Income Tax Expense (Benefit) -170K USD -121%
Net Income (Loss) Attributable to Parent -189M USD -27.9%
Earnings Per Share, Basic -2.72 USD/shares -16.2%
Earnings Per Share, Diluted -2.72 USD/shares -16.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 58.9M USD -15.3%
Marketable Securities, Current 641M USD +40%
Accounts Receivable, after Allowance for Credit Loss, Current 833K USD -62.5%
Assets, Current 707M USD +32.6%
Deferred Income Tax Assets, Net 400K USD +81%
Property, Plant and Equipment, Net 9.39M USD +17.8%
Operating Lease, Right-of-Use Asset 8.88M USD -12%
Assets 919M USD +27.7%
Employee-related Liabilities, Current 3.82M USD +43.1%
Liabilities, Current 22.2M USD -1.19%
Operating Lease, Liability, Noncurrent 9.1M USD -12.8%
Liabilities 31.3M USD -4.86%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.77M USD +2.8%
Retained Earnings (Accumulated Deficit) -713M USD -36%
Stockholders' Equity Attributable to Parent 888M USD +29.2%
Liabilities and Equity 919M USD +27.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.2M USD -25.5%
Net Cash Provided by (Used in) Financing Activities 354M USD +27%
Net Cash Provided by (Used in) Investing Activities -46.2M USD -199%
Common Stock, Shares, Issued 75.5M shares +19.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -89.7M USD -831%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 214M USD +30.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.27 pure 0%
Operating Lease, Liability 10.4M USD -10.3%
Payments to Acquire Property, Plant, and Equipment 188K USD -91.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -189M USD -27.2%
Lessee, Operating Lease, Liability, to be Paid 11.9M USD -12.1%
Operating Lease, Liability, Current 1.32M USD +10.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.82M USD +3.83%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.75M USD +3.99%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Deferred Income Tax Expense (Benefit) 403K USD +39.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.5M USD -22.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.8M USD -0.77%
Deferred Tax Assets, Operating Loss Carryforwards 120M USD +48.7%
Preferred Stock, Shares Issued 0 shares -100%
Unrecognized Tax Benefits 10.9M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.1M USD -38.9%
Operating Lease, Payments 411K USD +1.23%
Preferred Stock, Shares Outstanding 0 shares -100%
Deferred Tax Assets, Net of Valuation Allowance 802K USD +57.6%
Share-based Payment Arrangement, Expense 32.4M USD +58.9%